Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100604552 | 10060455 | 2 | F | 201403 | 20140923 | 20140404 | 20140930 | PER | CA-JNJFOC-20140319136 | JANSSEN | 62.17 | YR | A | M | Y | 96.00000 | KG | 20140930 | N | OT | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100604552 | 10060455 | 1 | PS | REMICADE | INFLIXIMAB | 1 | INTRAVENOUS | N | 0 | LYOPHILIZED POWDER | |||||||||
| 100604552 | 10060455 | 2 | SS | REMICADE | INFLIXIMAB | 1 | INTRAVENOUS | N | 103772 | 500 | MG | LYOPHILIZED POWDER |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 100604552 | 10060455 | 1 | Crohn's disease |
| 100604552 | 10060455 | 2 | Crohn's disease |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 100604552 | 10060455 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 100604552 | 10060455 | Gallbladder perforation | |
| 100604552 | 10060455 | Sepsis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 100604552 | 10060455 | 1 | 20140923 | 0 | ||
| 100604552 | 10060455 | 2 | 20101004 | 0 |